Skip to main content

Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin’s disease

  • Chapter
Annals of Oncology

Summary

The combination of chemotherapy and radiotherapy in Hodgkin’s disease has been associated with iatrogenic effects. Forty adult patients were studied to evaluate the early toxicity following three courses of ABVD (cumulative dose of doxorubicin [Adriamycin] 150 mg/m2, and bleomycin 60 mg) and mediastinal irradiation at 40 Gy. Cardiopulmonary toxicity was assessed from six months to three years after completion of irradiation. Of the 40 patients, all of whom were in complete remission from Hodgkin’s disease, 6 experienced dyspnea on exertion. In studies related to Cardiac toxicity, the left ventricular ejection fraction ranged from 50 to 77% (mean 63%); 8 patients had a minor pericardial effusion, 4 had valvular calcification, and 6 had minimal cardiac abnormalities. With regard to pulmonary toxicity, CT scan showed a small pleural effusion with pleural thickening in 19 patients and mediastinal or apical fibrosis in 15 patients. The total pulmonary capacity value was low (<80%), in 19 patients, and decreased carbon monoxide diffusion capacity (<70%) was found in 10 patients. We conclude that early cardiac toxicity was absent despite the use of Adriamycin and mediastinal irradiation. Pulmonary toxicity was present but minor, and it may decrease with the use of smaller fraction sizes for mantle field irradiation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hagemeister FB. Prognostic factors in decision making in the clinical management of Hodgkin’s disease. Hematol oncol 1988; 6: 257–69.

    Article  PubMed  CAS  Google Scholar 

  2. Blayney DW, Longo DL, Young RC et al. Decreasing risk of leukemia with prolonged follow up after chemotherapy and radiotherapy for Hodgkin’s disease. N Engl J Med 1987; 316: 710–4.

    Article  PubMed  CAS  Google Scholar 

  3. Coleman CN, Williams CJ, Flint A, Glastein EJ, Rosenberg SA, Kaplan HS. Hematologic neoplasia in patients treated for Hodgkin’s disease. N Engl J Med 1977; 297: 1249–52.

    Article  PubMed  CAS  Google Scholar 

  4. Bonadonna G, Valagussa P, Santoro A. Alternating non cross resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. Ann Intern Med 1986; 66: 1023–34.

    Google Scholar 

  5. Gottdiener JS, Katin MJ, Borer JS, Bacharach SL, Green MV. Late cardiac effect of therapeutic mediastinal irradiation. N Engl J Med 1983; 308: 569–71.

    Article  PubMed  CAS  Google Scholar 

  6. Gomez GA, Park JJ, Panahon AM et al. Heart size and function after radiation therapy to the mediastinum in patients with Hodgkin’s disease. Cancer Treat Rep 1983; 67: 1099–103.

    PubMed  CAS  Google Scholar 

  7. Green DM, Gingell RL, Pearce J, Panahon AH, Ghoorah J. The effect of mediastinal irradiation on cardiac function of patients treated during childhood and adolescence for Hodgkin’s disease. J Clin Oncol 1987; 5: 239–45.

    PubMed  CAS  Google Scholar 

  8. Dopico GA, Wiley AL, Rao P, Dickie HA. Pulmonary reaction to upper mantle radiation therapy for Hodgkin’s disease. Chest 1979; 75: 688–92.

    Article  CAS  Google Scholar 

  9. Cosset JM, Henry Amar H, Thomas J et al. Increased pulmonary toxicity in the ABVD arm of the EORTC H6 V trial. J Clin Oncol 1989; 8: abst. 985.

    Google Scholar 

  10. Lamonte CS, Yeh SDJ, Straus DJ. Long term follow up of cardiac function in patients with Hodgkin’s disease treated with mediastinal irradiation and combination chemotherapy including doxorubicin. Cancer Treat Rep 1986; 70: 439–44.

    PubMed  CAS  Google Scholar 

  11. Carbone PP, Kaplan HS, Musshoff K, Smithers PW, Tubiana M. Report of comittee on Hodgkin’s disease staging classification. Cancer Res 1971; 31: 1860–1.

    PubMed  CAS  Google Scholar 

  12. Behrewdt H, van Bunningen NF, van Leeuwen EF. Treatment of Hodgkin’s disease in children with or without radiotherapy. Cancer 1987; 59: 1870–3.

    Article  Google Scholar 

  13. Leeuwen FE, Somers R, Taal BG et al. Increased risk of lung cancer, non Hodgkin’s lymphoma and leukemia following Hodgkin’s disease. J Clin Oncol 1989; 7: 1046–58.

    PubMed  Google Scholar 

  14. Viviani S, Santoro A, Ragni G, Boufante V, Besfetti O, Bona-donna G. Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21: 601–5.

    Article  PubMed  CAS  Google Scholar 

  15. Bauer KAA, Skarin AT, Balikian JP, Garrick MB, Rosenthal DS, Canellos GR Pulmonary complications associated with combination chemotherapy programs containing Bleomycin. Am J Med 1983; 74: 557–63.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Brice, P. et al. (1991). Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin’s disease. In: Ultmann, J.E., Samuels, B.L. (eds) Annals of Oncology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7305-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-7305-4_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-7294-1

  • Online ISBN: 978-1-4899-7305-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics